Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of Pl3Kα-Selective Inhibitor RP903 (JS105) in Subjects With Advanced Malignancies

NCT06846099 is registered in ClinicalTrials.gov with Risen (Suzhou) Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT06846099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of Pl3Kα-Selective Inhibitor RP903 (JS105) in Subjects With Advanced Malignancies
Lead sponsor
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2022
Completion date
May 30, 2025
Enrollment
69 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, endometrial cancer, ovarian cancer, solid tumor cancer